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ORIGINAL ARTICLE 
Osteoblast-restricted Disruption of the Growth 
Hormone Receptor in Mice Results in Sexually 
Dimorphic Skeletal Phenotypes 
 
 
Vandana Singhal1, Brian C. Goh1, Mary L. Bouxsein2, Marie-Claude Faugere3, Douglas J. DiGirolamo1* 
 
1Department of Orthopaedic Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; 2Center for 
Advanced Orthopedic Studies, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA; 
3Albert B. Chandler Medical Center, University of Kentucky, Lexington, KY, USA 
Growth hormone (GH) exerts profound anabolic actions during postnatal skeletal development, in part, 
through stimulating the production of insulin-like growth factor-1 (IGF-1) in liver and skeletal tissues. To 
examine the requirement for the GH receptor (GHR) in osteoblast function in bone, we used Cre-LoxP 
methods to disrupt the GHR from osteoblasts, both in vitro and in vivo. Disruption of GHR from primary 
calvarial osteoblasts in vitro abolished GH-induced signaling, as assessed by JAK2/STAT5 phosphorylation, 
and abrogated GH-induced proliferative and anti-apoptotic actions. Osteoblasts lacking GHR exhibited 
reduced IGF-1-induced Erk and Akt phosphorylation and attenuated IGF-1-induced proliferation and 
anti-apoptotic action. In addition, differentiation was modestly impaired in osteoblasts lacking GHR, as 
demonstrated by reduced alkaline phosphatase staining and calcium deposition. In order to determine the 
requirement for the GHR in bone in vivo, we generated mice lacking the GHR specifically in osteoblasts 
(ΔGHR), which were born at the expected Mendelian frequency, had a normal life span and were of normal 
size. Three week-old, female ∆GHR mice had significantly reduced osteoblast numbers, consistent with the 
in vitro data. By six weeks of age however, female ΔGHR mice demonstrated a marked increase in 
osteoblasts, although mineralization was impaired; a phenotype similar to that observed previously in mice 
lacking IGF-1R specifically in osteoblasts. The most striking phenotype occurred in male mice however, 
where disruption of the GHR from osteoblasts resulted in a “feminization” of bone geometry in 16 week-old 
mice, as observed by μCT. These results demonstrate that the GHR is required for normal postnatal bone 
development in both sexes. GH appears to serve a primary function in modulating local IGF-1 action.  
However, the changes in bone geometry observed in male ΔGHR mice suggest that, in addition to facilitating 
IGF-1 action, GH may function to a greater extent than previously appreciated in establishing the sexual 
dimorphism of the skeleton. 
Keywords: growth hormone; osteoblasts; knockout mice; bone; sexual dimorphism 
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Introduction 
 
Bone acquisition and remodeling depend on the 
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coordinated activities of bone-forming osteoblasts and 
bone-resorbing osteoclasts. During postnatal develop- 
ment, the activity and lifespan of osteoblasts is regu- 
lated by many local growth factors, cytokines, and 
systemic hormones (1,2). Among these, growth hormone 
(GH) and insulin-like growth factor-1 (IGF-1) exert 
anabolic activity, particularly during the rapid phases of 
bone acquisition that occur during the pubertal growth 
Osteoblast-restricted disruption of growth hormone receptor 
 
Bone Research | Vol 1 No 1 | February 2013 
86 
spurt. GH is a cytokine peptide (3) produced and stored 
by somatotroph cells of the anterior pituitary. GH 
functions by binding to its homodimeric transmembrane 
GH receptor (GHR) and triggering conformational 
changes (4) that lead to activation of associated JAKs 
(5-7) to activate STATs (8-16), PI3K/Akt (17, 18) and ERK 
(19-21). GH-induced activation of STAT5b results in 
transcriptional activation of IGF-1 (20, 22-24). 
In many tissues, GH actions are mediated by its ability 
to stimulate the production of IGF-1, a widely expressed 
polypeptide that bears homology to pro-insulin. IGF-1 
signals primarily via the heterotetrameric type-1 IGF-1 
receptor (IGF-1R) to trigger ERK and PI3K/Akt activation 
via SHC and insulin receptor substrate-1 and -2 (IRS-1/2) 
(25,26). IGF-1 is an important growth and survival factor 
for many cell types, including osteoblasts (27,28).  IGF-1 
also plays a role in differentiation of fetal rat calvarial 
osteoblasts to augment type I collagen synthesis and 
inhibit collagen degradation (29). The role of IGF-1 in 
bone is well established. For example, osteoblast- 
specific over-expression of IGF-1 in mice accelerates 
new bone formation and also increases the rate at 
which matrix is mineralized (30). Conversely, osteoblast- 
specific disruption of the IGF-1R results in markedly 
impaired mineralization of trabecular bone (31). 
The precise role of GH in bone has been difficult to 
define due to the intimate linkage between GH and 
IGF-1 production. High affinity GH receptors are 
expressed in osteoblast-like cell lines (32, 33) and in 
primary mouse osteoblasts (34-36). In addition, GH has 
been shown to stimulate proliferation of cultured 
osteoblasts (33). Mice globally deficient in either IGF-1 or 
GH have impaired postnatal bone acquisition, with the 
defect being more severe in the IGF-1 nulls (37), 
suggesting that GH might exert actions independent of 
IGF-1 in bone. Moreover, treatment of IGF-1 null mice 
with GH significantly increases mineral apposition and 
bone formation rates (38). However, interpretation of 
these models is confounded by the overall growth 
retardation seen in these mice, as well as problems with 
reproductive hormone status.   
To overcome some of these potentially confounding 
problems, we used a Cre-LoxP strategy to create a 
mouse lacking GHR specifically in osteoblasts, which 
enabled us to determine the requirement of GHR for 
osteoblast function, both in vitro and in vivo. Our results 
demonstrate that the GHR is required for normal post- 
natal bone development in both sexes. As may be 
expected, GH appears to serve a primary function in 
modulating local IGF-1 action. Interestingly, osteoblast- 
restricted disruption of the GHR in male mice resulted in 
“feminization” of bone geometry in adult animals, 
suggesting GH may function to a greater extent than 
previously appreciated in establishing the sexual dimor- 
phism of the skeleton. 
 
Methods 
 
Materials  
Cell culture media, α-minimal essential medium (αMEM), 
was obtained from Cellgro-Mediatech (Herdon, VA) 
and fetal bovine serum (FBS) was from Gibco (Gaithers- 
burg, MD). Bovine GH was obtained from the National 
Hormone and Peptide Program-Monsanto (Torrance, 
CA) and stored in 200X aliquots for single use. Human 
IGF-1 was obtained from GroPep (Theberton, SA, Austra- 
lia) and stored in 1 000X aliquots for single use. Antibodies 
used for immunoblotting included anti-βactin (C4) from 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA); anti- 
phospho-JAK2 (Tyr1007/1008), anti-JAK2, anti-phospho- 
STAT5 (Tyr 694), anti-STAT5, anti-phospho-Akt (Ser 473), 
anti-Akt, anti-phospho-ERK (Thr202/Tyr204), anti-ERK, anti- 
IGF-1R from Cell Signaling Technology (Danvers, MA), 
and anti-GHR AL47(a generous gift from Dr. Stuart Frank, 
University of Alabama at Birmingham, Birmingham, AL). 
Horseradish-peroxidase conjugated rabbit and mouse 
secondary antibodies were obtained from Pierce Bio- 
technology (Rockford, IL). Polyvinylidenedifluoride (PVDF) 
membrane, Laemmeli sample buffer and other electro- 
phoresis supplies were from Bio-Rad. Assay kits for flow 
cytometry analysis of cell proliferation were purchased 
from BD Pharmingen (San Jose, CA). All other reagents 
not specified here were purchased from Sigma.  
 
Osteoblast isolation and culture 
Osteoblasts were isolated from calvaria of newborn 
GHRfl/fl mice by serial digestion in 1.8 mg·mL-1 collagen- 
ase type I (Worthington, Lakewood, NJ) solution. Cal- 
varia were digested in 10 mL of digestion solution for 15 
min at 37℃  with constant agitation. The digestion 
solution was collected, and digestion was repeated with 
fresh digestion solution an additional four times. Diges- 
tions 3–5 (containing the osteoblasts) were pooled toge- 
ther, centrifuged, washed with αMEM containing 10% 
FBS, 1% pen/strep, and plated overnight at 37℃ in a 
humidified incubator supplied with 5% CO2. For in vitro 
deletion of the GHR, GHR floxed osteoblasts were 
cultured to be 70% confluent and then, in the absence 
of serum, were infected with adenovirus encoding Cre 
recombinase (Ad-Cre) (Vector Biolabs, Philadelphia, PA) 
at a titer of 100 multiplicity of infection (moi). Infection 
with 100 moi of adenovirus encoding green fluorescent 
protein (Ad-GFP) (Vector Biolabs) was used as control. 
After 1 hour, culture medium containing 10% FBS was 
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added and the cells were allowed to recover for the 
next 48 h. Greater than 90% GHR deletion was confirm- 
ed for every infection by quantitative real-time PCR 
analysis and immunoblotting. For differentiation, osteo- 
blasts were grown to confluence and then switched to 
differentiation media supplemented with β–glycero- 
phosphate and ascorbic acid for 7 days prior to alkaline 
phosphatase staining or 14 days prior to alizarin red S 
staining by standard methods. 
 
Cell lysis and immunoblotting analysis 
For signaling experiments, osteoblasts were cultured in 
αMEM containing 10% FBS, until 90% confluent, and then 
serum starved in αMEM containing 0.1% FBS for 24 hours 
to reduce cellular activity to quiescent levels prior to 
stimulation. At the end of the study, the cells were 
washed twice with ice-cold phosphate-buffered saline 
(PBS) and resuspended in lysis buffer (50 mmol·L-1 Tris (pH 
7.4), 150 mmol·L-1 NaCl, 1 mmol·L-1 MgCl2, 1 mmol·L-1 
EDTA, 1% Triton X-100, and 10% glycerol). Protease and 
phosphatase inhibitors (Sigma) were added to the lysis 
buffer. The cell lysates were homogenized by needle 
aspiration and protein concentration was measured by 
Bradford protein assay (Bio-Rad). For immunoblotting of 
whole cell lysates, equal amounts of protein (10 or 20 µg 
per lane) were solubilized in Laemmeli sample buffer and 
loaded onto a mini-SDS-PAGE system. Following electro- 
phoresis, proteins were transferred to a PVDF membrane 
using a Bio-Rad semi-dry transfer system. Protein transfer 
efficiency was verified using pre-stained protein markers.  
Membranes were then blocked with 5% non-fat dry milk 
for 1 hour at room temperature and subsequently 
incubated overnight at 4 ℃ with antibodies directed 
against the protein of interest.  Signals were detected 
using a horseradish peroxidase-conjugated secondary 
antibody and bound antibodies were visualized using 
the Supersignal West Femto Substrate (Pierce). Western 
blot photographic results were scanned with a Canon 
flatbed scanner.   
 
Quantitative real-time PCR 
Total RNA was extracted from cells using the TRIzol® 
method, as recommended by the manufacturer (Invitro- 
gen). The RNA concentration was estimated spectro- 
photometrically and only pure RNA (A260:A280 ratio ≥ 
1.8) was used for further analysis. First strand cDNA was 
synthesized using the iScript cDNA Synthesis Kit (Bio-Rad). 
The cDNA was amplified in the Opticon Continuous 
Fluorescent Detector (MJ Research, Waltham, MA) using 
IQTM SYBR Green supermix (Bio-Rad) and sequence 
specific primers. PCR reactions were performed in 
triplicate for each cDNA, averaged, and normalized to 
endogenous β-actin reference transcripts. Primer 
sequences used were as follows: GHR: F5’-GATTTTACC- 
CCCAGTCCCAGTTC-3’, R5’-GACCCTTCAGTCTTCTCAT- 
CCACA-3’; β-actin: F5’-ACCTCCTACAATGAGCTGC-3’, 
R5’-TGCCAATAGTGATGACCT-3’. 
 
Osteoblast proliferation assays 
Osteoblasts were plated in 6-well plates at low cell 
density (9 x 104 cells per well) and cultured in αMEM 
containing 1% FBS for 24 hours to arrest the cells in G0 
phase. The cells were then stimulated with 500 ng·mL-1 
GH or 100 ng·mL-1 IGF-1 for 48 hours. For proliferation 
analysis of the cells, 10 µmol·L-1 BrdU was added to the 
medium at the time of mitogenic stimulation. The cells 
were then stained with anti-BrdU-APC and 7-AAD and 
analyzed by FACS Calibur (Becton-Dickson). 20 000 
events were collected for each sample and results were 
analyzed with WinMDI version 2.8. 
 
Osteoblast apoptosis assays 
Osteoblasts were plated at confluence in 96 well plates 
in 1% FBS containing media. They were then pretreated 
for 24 hours with GH or IGF-1 before induction of apop- 
tosis (8 ng·mL-1 staurosporine). Apoptosis was assessed 
by PromegaCaspaseGlo 3/7 according to manu- 
facturer’s instructions after 8 hours. 
 
Animal studies 
Osteoblast-restricted disruption of the GHR was achieved 
by crossing mice carrying floxed GHR alleles (GHRfl/fl) (39) 
with mice expressing the Cre recombinase under the 
control of the human osteocalcin promoter (OC-Cre) 
(31). Recombination was confirmed in skeletal tissues by 
allele specific PCR using a forward primer upstream of 
the floxed exon 4 of GHR, in combination with two re- 
verse primers-one within the floxed exon 4 that resulted 
in ~720 bp product and one downstream of exon 4 that 
resulted in ~1 300 bp product following recombination. 
Male and female control (GHRfl/fl) and ΔGHR (GHRfl/fl 
OC-Cre+) mice were sacrificed at 3, 6, and 16 weeks of 
age and femurs were removed and fixed in 100% 
ethanol. Prior to sacrifice, 3- and 6-week-old mice were 
administered intraperitoneal injections of 100 µL of a 1% 
calcein solution (to assess dynamic histomorphometric 
parameters) on a split dose schedule leaving 3 days (for 
3-week-old animals) or 5 days (for 6-week-old animals) 
between the first and second dose, and 2 days (3- 
week-old) or 3 days (6-week-old) following the second 
dose before sacrifice. Micro-computed tomography 
analysis (μCT) of the femur was performed at the 
Orthopedic Biomechanics Laboratory at Beth Israel 
Deaconess Medical Center (Boston, MA) and at the 
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Center for Musculoskeletal Research at Johns Hopkins 
University. For histomorphometric analysis, femurs were 
embedded and sectioned. Five serial sections were 
stained using the Masson-Goldnertrichrome technique, 
and five more serial sections were left unstained for 
fluorescent microscopy. Static and dynamic parameters 
of bone structure and formation were measured at the 
Albert B. Chandler Medical Center at the University of 
Kentucky (Lexington, KY). 
 
Statistical analysis 
All statistical analyses were performed using the Micro- 
soft Excel data analysis program for ANOVA or Student’s 
t-test analysis with an assigned significance level of 0.05 
(α). All experiments were repeated at least three times 
unless otherwise stated. Values are expressed as a 
mean±S.E.M. 
 
Results 
 
Disruption of GHR in osteoblasts in vitro abolishes GH 
signaling and attenuates IGF-1 activity 
To examine the requirement of GHR for osteoblast 
function in vitro, primary osteoblasts from mice carrying 
homozygous floxed GHR alleles were infected with 
Cre-expressing adenovirus constructs (AdCre) or adeno- 
virus expressing GFP as a control (GFP). Real time PCR 
analysis of GHR mRNA expression (Figure 1A) showed a 
90% reduction in GHR mRNA in osteoblasts infected with 
100 moi of AdCre and a complete loss of GHR protein 
(Figure 1B). Importantly, IGF-1R protein levels were 
unaffected in AdCre cells (Figure 1B), and infection of 
wild-type (non-floxed) osteoblasts with AdCre had no 
discernable effects on basal, GH- or IGF-1-induced ERK 
or Akt phosphorylation (not shown). GH-induced JAK2, 
STAT5 and ERK phosphorylation were completely 
abolished (Figure 1C) following GHR disruption. 
Previous studies have described a functional inter- 
dependence between GHR and IGF-1R, such that the 
presence of both receptors is required for each receptor 
to exert its full competency (40). We therefore examined 
IGF-1-induced signals in osteoblasts following disruption 
of GHR. IGF-1-induced ERK activation was blunted in 
AdCre osteoblasts compared to GFP osteoblasts, and 
Akt phosphorylation was also reduced (Figure 1C). These 
results suggest that, in accord with previous observations, 
GHR is required for full potency of IGF-1R signaling. 
 
Disruption of GHR reduces the proliferative and anti- 
apoptotic effects of IGF-1 
To assess the effect of the GHR on osteoblast prolifera- 
tion, GFP and AdCre osteoblasts were serum starved for 
24 hours and then treated with vehicle, GH or IGF-1. BrdU 
incorporation, indexed at 48 hours by flow cytometry, 
showed that both GH and IGF-1 significantly induced 
BrdU uptake in GFP control cells (Figure 2A). Disruption of 
GHR abolished GH-induced BrdU uptake and blunted 
IGF-1-induced BrdU uptake as well (Figure 2A), consis- 
tent with the attenuation of IGF-1 signaling observed in 
the AdCre osteoblasts above (Figure 1C). To determine 
the requirement of the GHR for osteoblast survival, GFP 
and AdCre osteoblasts were pre-treated with vehicle, 
GH or IGF-1 in 1% serum containing media, and then 
exposed to staurosporine to induce apoptosis. In GFP 
control osteoblasts, both GH and IGF-1 significantly 
attenuated staurosporine-induced apoptosis as 
measured by caspase 3/7 activation (Figure 2B). As 
expected, disruption of GHR abolished the anti-apop- 
totic activity of GH (Figure 2B). Moreover, the ability of 
IGF-1 to attenuate staurosporine-induced apoptosis was 
also eliminated in ΔGHR osteoblasts (Figure 2B). 
 
Disruption of GHR impairs osteoblast differentiation in 
vitro 
To then assess the effect of GHR signaling on osteoblast 
differentiation in vitro, GFP and AdCre osteoblasts were 
grown to confluence and before being switched to 
differentiation media supplemented with β–glycero- 
phosphate and ascorbic acid. AdCre osteoblasts 
demonstrated a modest, but consistent, reduction in 
alkaline phosphatase staining at seven days of culture 
(Figure 2C) and calcium deposition at 14 days of culture 
(Figure 2D). Taken together, these in vitro data suggest 
that the GHR is required for normal osteoblast function, 
and further, that loss of the GHR appears to blunt IGF-1R 
function in osteoblasts. 
 
Osteoblast-restricted disruption of GHR in vivo 
To determine the requirement of the GHR for osteoblast 
function in vivo, we conditionally disrupted the GHR in 
osteoblasts (ΔGHR mice) by crossing GHR floxed mice 
(GHRfl/fl) with mice that express the Cre recombinase 
under the control of the human osteocalcin promoter 
(OC-Cre). ΔGHR mice were born at the expected 
Mendelian frequency, had a normal life span, and 
exhibited no differences in body weight or length com- 
pared to control littermates (not shown). Allele-specific 
PCR, to identify both the floxed and recombined GHR 
alleles, demonstrated that recombination occurred only 
in bone tissues of ΔGHR mice (Figure 3A). μCT measure- 
ments were performed at 3, 6 and 16 weeks of age in, 
both male and female, control and ΔGHR mice. 
Representative cross-section images of trabecular bone 
at the distal femur (left) and cortical bone at the femoral 
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Figure 1 Cre-mediated excision of GHR from primary mouse osteoblasts abolishes GH signaling and attenuates IGF-1 signaling. Calvarial osteoblasts 
isolated from newborn mice carrying floxed GHR alleles were infected with AdGFP as control or AdCre for deletion. After two days in culture, GHR 
mRNA expression was assessed by real-time PCR (A), and protein levels of GHR and IGF-1R were analyzed by immunoblotting (B). GFP or AdCre 
osteoblasts were grown to confluence and serum starved for 24 hours before stimulation with vehicle, GH or IGF-1 for 10 minutes. Cells were lysed and 
cell lysates immunoblotted with anti-phospho-JAK2 (arrow) and anti-JAK2, anti-phospho-STAT5 and anti-STAT5, anti- phospho-ERK and anti-ERK, or 
anti-phospho-Akt and anti-Akt (C). Graphs represent densitometric analysis of three experiments. *P<0.05 
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Figure 2 Proliferative and anti-apoptotic actions of IGF-1, as well as osteoblast differentiation, are blunted in osteoblasts lacking GHR. GFP and AdCre 
osteoblasts were cultured at low density and serum starved for 24 hours before stimulation with GH or IGF-1 to induce proliferation. Proliferation was 
assessed by BrdU incorporation (A). GFP and AdCre osteoblasts were plated at confluence in 1% FBS containing media and pretreated for 24 hours with 
GH or IGF-1 before induction of apoptosis (8 ng·mL-1 staurosporine). Apoptosis was assessed by Promega Caspase- Glo 3/7 after eighthours (B). GFP and 
AdCre osteoblasts were grown to confluence and then switched to differentiation media for seven days prior to alkaline phosphatase staining (C) or 14 
days prior to alizarin red S staining and calcium quantification (D). *P< 0.05 
 
midshaft (right) are shown (Figure 3B-Female, Figure 
3C-Male). Complete μCT data for all groups can be 
found in Table 1. Histomorphometric analysis was 
performed on the contralateral femur of these same 
animals, and complete morphometric data are listed in 
Table 2. 
In female ΔGHR mice, μCT analysis revealed only 
modest changes throughout postnatal development, 
including a slight increase in cortical thickness and cross- 
sectional area at three weeks of age and slight cortical 
thinning at six weeks of age, when compared to controls 
(Figure 3B and Table 1). However, histomorphometric 
analysis of trabecular bone in the distal femur revealed 
a phenotype strikingly similar to that previously observed 
in female mice with osteoblast-restricted disruption of 
the IGF-1R (31). At three weeks of age, female ΔGHR 
mice had less than half the numbers of osteoblasts seen 
in control mice (Figure 4A). The reduction in osteoblasts 
in female ΔGHR mice reversed by six weeks of age, such 
that female ΔGHR mice increased to twice the number 
of osteoblasts seen in control animals at six weeks (Figure 
4B)-again, similar to previous observations in female 
mice lacking IGF-1R in osteoblasts at six weeks of age. 
Consistent with the in vitro differentiation results, osteo- 
blasts in six-week-old female ΔGHR mice appeared to 
be functionally impaired, as indicated by reduced bone 
formation rate per osteoblast and a trend toward in- 
creased mineralization lag time (Figure 4C and 4D).  
In contrast to female mice, male ΔGHR mice with 
osteoblast-restricted disruption of the GHR exhibited a 
skeletal phenotype with age that could be easily 
appreciated by μCT analysis (Figure 3C and Table 1). 
While there were no significant changes observed by 
μCT at earlier ages, 16-week-old male ΔGHR mice had 
significantly smaller bones than control animals that 
appeared remarkably similar to bones from female 
animals, with reduced trabecular bone volume and 
significantly smaller medullary area (Figure 5A and 5B). 
Although no differences were observed in osteoblast 
numbers between control and ΔGHR mice at 16 weeks 
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Table 1 μCT analysis 
Female Control   ΔGHR 
 3 weeks (n=5) 6 weeks (n=6) 16 weeks (n=5)   3 weeks (n=6) 6 weeks (n=5) 16 weeks (n=7) 
Trabecular 
parameters 
BV/TV (%) 13.16 ± 1.07 14.99 ± 1.70 14.80 ± 1.64   15.71 ± 1.35 14.95 ± 1.00 13.33 ± 1.71 
Tb.N (mm-1) 4.83 ± 0.24 4.30 ± 0.30 4.33 ± 0.17   5.80 ± 0.40 4.61 ± 0.18 4.19 ± 0.27 
  Tb.Th (mm) 38.57 ± 0.52 49.57 ± 0.50 53.60 ± 1.10   39.32 ± 0.70 48.42 ± 0.44 51.96 ± 0.87 
  Tb.Sp (mm) 224.33 ± 9.35 239.63 ± 16.85 228.48 ± 10.49   190.38 ±14.91   216.98 ± 8.30  239.94 ±18.09   
Cortical 
parameters 
Ct.Th (mm) 89.67 ± 5.24 148.17 ± 4.74 190.80 ± 4.49   101.83 ± 3.15a   136.80 ± 2.82a   192.14 ± 6.41 
Ct.Ar (mm2) 0.30 ± 0.03 0.59 ± 0.03 0.71 ± 0.03   0.34 ± 0.02 0.54 ± 0.03 0.72 ± 0.03 
  Tt.Ar (mm2) 1.02 ± 0.07 1.57 ± 0.08 1.50 ± 0.06   1.02 ± 0.07 1.53 ± 0.12 1.49 ± 0.06 
  Ma.Ar (mm2) 0.68 ± 0.05 0.99 ± 0.05 0.77 ± 0.04   0.72 ± 0.05 0.99 ± 0.09 0.79 ± 0.05 
  Ct.Ar/Tt.Ar (%) 29.57 ± 1.08 37.37 ± 0.85 47.71 ± 0.94   33.43 ± 0.59a   35.47 ± 1.04 48.47 ± 1.63 
Male Control   ΔGHR 
 3 weeks (n=5) 6 weeks (n=5) 16 weeks (n=5)   3 weeks (n=5) 6 weeks (n=8) 16 weeks (n=5) 
Trabecular 
parameters 
BV/TV (%) 12.88 ± 0.82 22.39 ± 1.28 14.28 ± 1.08   13.95 ± 0.97 23.37 ± 2.01 9.73 ± 0.60a 
Tb.N (mm-1) 5.21 ± 0.41 6.05 ± 0.22 4.76 ± 0.14   5.00 ± 0.10 6.00 ± 0.25 4.14 ± 0.10a 
  Tb.Th (mm) 38.92 ± 0.52 50.56 ± 1.96 50.80 ± 0.74   39.10 ± 0.80 52.09 ± 3.33 49.75 ± 1.87 
  Tb.Sp (mm) 211.88 ± 19.21 161.16 ± 6.83 207.78 ± 6.43   214.77 ± 4.45 164.48 ± 9.05 238.78 ± 5.78a 
Cortical 
parameters 
Ct.Th (mm) 98.80 ± 3.07 154.80 ± 4.35 209.00 ± 4.23   97.67 ± 1.86 163.25 ± 3.29 206.43 ± 5.70 
Ct.Ar (mm2) 0.34 ± 0.02 0.65 ± 0.05 0.88 ± 0.01   0.36 ± 0.03 0.70 ± 0.04 0.83 ± 0.06 
  Tt.Ar (mm2) 1.05 ± 0.06 1.68 ± 0.15 1.92 ± 0.07   1.20 ± 0.13 1.84 ± 0.13 1.68 ± 0.14 
  Ma.Ar (mm2) 0.72 ± 0.04 1.04 ± 0.10 1.07 ± 0.05   0.84 ± 0.10 1.14 ± 0.10 0.88 ± 0.07a 
  Ct.Ar/Tt.Ar (%) 32.09 ± 0.68 38.64 ± 0.78 46.39 ± 1.34   30.14 ± 0.80 38.74 ± 1.20 49.74 ± 1.04a 
Trabecular parameters were assessed at the distal femur and cortical parameters at the femoral midshaft. BV/TV–bone volume fraction; Tb.N–trabecular 
number; Tb.Th–trabecular thickness; Tb.Sp–trabecular separation; Ct.Th–average cortical thickness; Ct.Ar–cortical bone area; Tt.Ar–total cross-sectional 
area (inside periosteal envelope); Ma.Ar–medullary area; Ct.Ar/Tt.Ar–cortical area fraction. Values shown are mean±SEM.  
aP<0.05 vs. age-matched control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 Osteoblast-specific disruption of the GHR in vivo results in sexually dimorphic skeletal changes. Allele-specific PCR confirms recombination 
occurs only in skeletal tissues of ΔGHR mice (A). Representative μCT images of cross sections of trabecular bone in the distal femur (left) and cortical bone 
in the femoral midshaft (right) from control and ΔGHR mice at the indicated ages are shown for female (B) and male (C) mice. 
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Table 2 Bone histomorphometry 
Female 
Control   ΔGHR 
3 weeks (n=5) 6 weeks (n=6) 16 weeks (n=5)   3 weeks (n=6) 6 weeks (n=5) 16 weeks (n=7) 
Bone 
Structure 
   
BV/TV (%) 5.28 ± 0.79 8.14 ± 1.53 10.86 ± 1.87   7.48 ± 0.64a 8.21 ± 0.83 8.06 ± 1.00a 
Tb.Th (mm) 16.85 ± 2.01 23.67 ± 1.68 26.29 ± 2.90   19.24 ± 1.34 22.59 ± 1.27 23.55 ± 1.47 
Tb.Sp (mm) 305.20 ± 13.10 272.39 ± 21.14 230.98 ± 26.05   246.02 ± 26.64a 275.09 ± 39.11 303.93 ± 55.05 
Bone 
Formation 
  
  
  
  
OV/BV (%) 5.08 ± 1.31 1.98 ± 0.35 4.73 ± 0.47   2.91 ± 0.49a 6.19 ± 1.58a 4.34 ± 1.42 
OS/BS (%) 21.42 ± 5.00 12.53 ± 2.24 21.25 ± 1.40   13.82 ± 2.10a 26.83 ± 4.68a 19.32 ± 3.26 
O.Th (mm) 1.95 ± 0.19 1.93 ± 0.23 2.88 ± 0.27   1.99 ± 0.23 2.52 ± 0.42 2.29 ± 0.23 
Ob.S/BS (%) 23.81 ± 6.95 10.25 ± 2.47 7.57 ± 1.72   7.04 ± 2.67a 20.73 ± 2.22a 10.07 ± 3.67 
N.Ob/B.Pm 
(no./100mm) 
3256.37 ± 1074.69 1065.70 ± 234.94 822.50 ± 159.03   1063.82 ± 360.88a 2433.80 ± 302.03a 1093.11 ± 392.20 
Bone 
Erosion 
  
  
  
ES/BS (%) 6.25 ± 1.15 9.55 ± 0.84 8.51 ± 2.19   7.04 ± 1.24 6.49 ± 2.38a 6.85 ± 1.06 
E.De (mm) 5.96 ± 1.23 4.84 ± 0.28 6.81 ± 0.26   6.03 ± 0.27 6.16 ± 0.41a 6.96 ± 0.33 
Oc.S/BS (%) 6.01 ± 1.20 7.95 ± 0.80 7.62 ± 2.03   9.35 ± 3.24 5.25 ± 1.96a 5.86 ± 0.94 
N.Oc/B.Pm 
(no./100mm) 
333.58 ± 100.17 379.94 ± 31.49 373.06 ± 
98.63 
  455.53 ± 136.94 306.34 ± 98.73 318.96 ± 44.21 
Bone 
Dynamics 
  
  
  
  
MAR (day) 0.90 ± 0.16 1.60 ± 0.24     0.83 ± 0.12 1.31 ± 0.08   
MS/BS (%) 12.48 ± 1.52 15.11 ± 2.21     13.95 ± 2.26 21.34 ± 3.58a   
BFR/BS 
(μm3/μm2/d) 
3.96 ± 0.58 8.27 ± 1.23     4.50 ± 1.42 10.28 ± 2.07   
BFR/N.Ob 
(mm2/Ob/y) 
2.02 ± 1.23 9.62 ± 2.22     12.47 ± 6.12a 4.35 ± 0.87a   
Mlt (day) 5.11 ± 1.64 1.67 ± 0.66     3.39 ± 0.73 3.09 ± 0.81   
Male 
Control   ΔGHR 
3 weeks (n=5) 6 weeks (n=5) 16 weeks (n=5)   3 weeks (n=5) 6 weeks (n=8) 16 weeks (n=5) 
Bone 
Structure 
   
BV/TV (%) 7.93 ± 1.75 7.00 ± 1.04 7.97 ± 2.94   7.33 ± 1.64 10.97 ± 1.59a 6.71 ± 1.01 
Tb.Th (mm) 17.16 ± 1.69 23.12 ± 1.15 24.57 ± 2.40   15.90 ± 3.01 26.77 ± 1.99 21.17 ± 1.08 
Tb.Sp (mm) 224.15 ± 38.92 333.33 ± 51.57 448.96 ± 137.20   204.27 ± 15.89 242.38 ± 30.04a 306.35 ± 28.09 
Bone 
Formation 
  
  
  
  
OV/BV (%) 4.13 ± 1.01 1.34 ± 0.60 5.16 ± 1.33   4.65 ± 2.12 2.15 ± 0.59 5.77 ± 2.64 
OS/BS (%) 17.35 ± 3.81 6.70 ± 2.16 22.02 ± 6.22   13.53 ± 2.42 10.98 ± 2.52 23.36 ± 6.22 
O.Th (mm) 1.95 ± 0.13 2.05 ± 0.27 2.94 ± 0.24   2.26 ± 0.18 2.47 ± 0.33 2.29 ± 0.36 
Ob.S/BS (%) 9.20 ± 3.00 7.18 ± 4.85 2.80 ± 1.30   11.77 ± 0.52 10.39 ± 2.02 2.00 ± 0.58 
N.Ob/B.Pm 
(no./100mm) 
1216.61 ± 248.42 567.28 ± 325.23 263.12 ± 106.59   1735.86 ± 119.14a 1016.92 ± 207.13 228.74 ± 68.71 
Bone 
Erosion 
  
  
  
ES/BS (%) 7.10 ± 1.26 3.61 ± 0.79 6.88 ± 1.02   8.26 ± 0.52 3.30 ± 0.78 3.94 ± 1.02a 
E.De (mm) 6.65 ± 0.93 6.16 ± 0.30 6.59 ± 0.65   5.07 ± 0.23 6.87 ± 0.74 5.05 ± 0.35a 
Oc.S/BS (%) 6.25 ± 1.17 3.03 ± 0.59 5.58 ± 0.57   6.96 ± 0.52 2.92 ± 0.74 3.63 ± 0.97a 
N.Oc/B.Pm 
(no./100mm) 
338.43 ± 72.74 165.52 ± 21.63 289.08 ± 26.85   446.65 ± 59.48 137.87 ± 35.86 157.53 ± 25.60a 
Bone 
Dynamics 
  
  
  
  
MAR (day) 1.13 ± 0.14 2.05 ± 0.18     0.89 ± 0.19 1.86 ± 0.17   
MS/BS (%) 12.16 ± 3.22 20.54 ± 4.77     11.71 ± 1.67 17.33 ± 2.43   
BFR/BS 
(μm3/μm2/d) 
5.54 ± 2.25 15.41 ± 4.18     3.99 ± 1.20 12.49 ± 2.71   
BFR/N.Ob 
(mm2/Ob/y) 
5.15 ± 2.21 64.61 ± 31.04     2.25 ± 0.62 14.81 ± 2.52a   
Mlt (day) 3.24 ± 0.48 0.38 ± 0.08     4.39 ± 1.66 1.14 ± 0.32a   
Histomorphometry was performed in trabecular bone of the distal femur. BV/TV–Bone volume/tissue volume; Tb.Th–Trabecular thickness; Tb.Sp– 
Trabecular separation; OV/BV–Osteoid volume/bone volume; OS/BS–Osteoid surface/bone surface; O.Th–Osteoid thickness; Ob.S/BS–Osteoblast 
surface/bone surface; N.Ob/B.Pm–Osteoblast number/bone perimeter; ES/BS–Erosion surface/bone surface; E.De–Erosion depth; Oc.S/BS–Osteoblast 
surface; N.Oc/B.Pm–Osteoclast number/bone perimeter; MAR–Mineral apposition rate; MS/BS–Mineralizing surface/bone surface; BFR/BS–Bone 
formation rate/bone surface; BFR/N.Ob–Bone formation rate/osteoblast; Mlt–Mineralization lag time. Values shown are mean±S.E.M.  
aP<0.05 vs. age-matched control 
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Figure 4 Selected histomorphometric parameters from 3-week (A) and 6-week (B, C and D) female mice. *P<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Select μCT (A and B) and histomorphometric parameters (C) from male mice. *P<0.05 
 
of age, osteoblasts in male ΔGHR mice at six weeks of 
age appeared to perform more poorly than in control 
animals, as indicated by a significantly reduced bone 
formation rate per osteoblast (Figure 5C). Unfortunately, 
this dynamic histomorphometric measurement cannot 
be performed in 16-week-old mice to directly assess 
osteoblast activity at this age. Together, these in vivo 
data suggest that, although much of GH action in 
promoting skeletal development would appear to result 
from stimulating IGF-1 production, the GHR plays a 
distinct role in establishing the sexual dimorphism 
observed in the skeleton of adult mice. 
Discussion 
 
In this study, we used a genetic approach to disrupt the 
GHR in an osteoblast-restricted manner, enabling us to 
distinguish the contribution of GHR mediated signals to 
osteoblast function. The loss of GHR in osteoblasts in vitro 
diminished both the proliferative and anti-apoptotic 
effects of IGF-1 and impaired modestly osteoblast 
differentiation. Interestingly, osteoblasts lacking GHR 
had normal levels of IGF-1R protein but demonstrated 
reduced IGF-1-induced ERK and Akt phosphorylation. 
This result suggests that the presence of the GHR protein 
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itself is required for full signaling efficacy of the IGF-1R, in 
agreement with previous studies that have described 
synergistic interactions between the GHR and IGF-1R. For 
example, in GHR expressing melanocytes, GH adminis- 
tration alone had no effect on proliferation, whereas 
IGF-1 significantly increased cell numbers, and the com- 
bination of both growth factors amplified this response 
by 50% (41). In addition, GH pre-treatment of cultured 
human osteoblasts increased osteoblast sensitivity to 
subsequent IGF-1 treatment (42). Moreover, previous 
work from our group (40) showed that GH-induced 
STAT5 phosphorylation is attenuated in mouse osteo- 
blasts that lack the IGF-1R. Together, these observations 
suggest the presence of a mechanism whereby the 
response of these cell types to GH and IGF-1 is maximal 
only when both receptors are present. One possible 
mechanism is suggested by studies of Huang et al (43), 
who demonstrated that increased GH signaling potency 
in pre-adipocytes involves a physical interaction be- 
tween GHR, JAK2 and IGF-1R. In their studies, JAK2 
physically associated with GHR and IGF-1R, and this 
complex then bound and phosphorylated SHC to 
activate downstream signaling pathways (44). In this 
scenario, loss of GHR and the associated JAK2 kinase 
may cause impaired IGF-1-induced recruitment and/or 
phosphorylation of SHC-Grb2-SOS. Such a mechanism 
would be compatible with the reduced IGF-1-induced 
ERK and Aktphosphorylation seen in our ΔGHR osteo- 
blasts. Additional studies, to more definitively character- 
ize the molecular mechanisms that mediate GHR/IGF-1R 
interact ions , are ongoing in our  laboratory .  
The changes observed in skeletal phenotype following 
loss of the GHR in vivo suggest both distinct and over- 
lapping roles for GH and IGF-1 in postnatal bone 
acquisition. The histomorphometric changes observed in 
trabecular bone in female ΔGHR mice closely 
resembled those described previously in female mice 
lacking the IGF-1R in osteoblasts (31). For example, both 
female ΔGHR and ΔIGF-1R mutants demonstrated 
reduced trabecular osteoblast numbers at three weeks 
of age. These findings are compatible with the current in 
vitro observations of abolished GH-induced, and sub- 
sequent blunting of IGF-1-induced, proliferative/anti- 
apoptotic actions, demonstrating the importance of 
GH/IGF-1 in regulating osteoblast numbers in early 
development. Unlike female mice lacking IGF-1R in 
osteoblasts however, three-week-old female ΔGHR 
mice did not have lower bone volume compared to 
control animals. By contrast, female ΔGHR mice actually 
had increased trabecular bone volume at this age 
despite the reduction in osteoblast numbers, likely 
resulting from a dramatic increase in bone formation 
rate per osteoblast (12.47±6.12 vs. 2.02±1.23 mm2/Ob/ 
yin controls). The increase in trabecular bone volume, 
despite reduced osteoblast numbers at three weeks of 
age in female ΔGHR mice, suggests that up-regulation 
of local IGF-1 via mechanisms other than GH might be 
able to compensate for the lack of GH-induced IGF-1 
production from osteoblasts in control animals. In 
support of this notion, three-week-old, female transgenic 
mice in which IGF-1 was over-expressed specifically in 
osteoblasts had increased trabecular bone volume and 
dramatically increased measures of bone formation, 
with no change in the number of osteoblasts (30). By six 
weeks of age, female ΔGHR mice had nearly twice the 
number of osteoblasts compared to control animals and 
increased mineralization lag time; a histological picture, 
again, analogous to that previously observed in ΔIGF-1R 
mice (31). It appears likely that the increased numbers of 
osteoblasts in both mutants represent compensation by 
other growth factors in response to loss of GH/IGF-1 
action. The inability to maintain normal bone volume 
later in life, despite the increase in osteoblast numbers, 
may relate to the reduced differentiation capacity 
observed in osteoblasts lacking the GHR in vitro. In 
addition, this deficiency in bone volume could owe to 
other components of the GH/IGF-1 system, namely, IGF 
binding proteins (IGFBP). For example, IGFBP5 levels 
increased dramatically at three weeks of age in the 
IGF-1 over-expressing mice mentioned above, coinci- 
dent with the increase in osteoblast function (45). 
However, IGFBP5 levels decreased by six weeks of age, 
in both wild type and transgenic mice, when osteoblast 
activity had returned to normal in the IGF-1 over- 
expressing mice; presenting the possibility that reduced 
matrix-bound IGFBP5 might diminish the capacity of 
IGF-1 to stimulate bone formation in older animals (45), 
since matrix-bound IGFBP5 has been shown to 
potentiate IGF signaling (46, 47).   
The alterations described above in female ΔGHR mice 
suggest significant overlap in GH and IGF-1 function in 
osteoblasts. Namely, GH appears to stimulate local IGF-1 
production, and the GHRfacilitates maximal IGF-1 
action. However, the dramatic skeletal phenotype 
observed in 16-week-old male ΔGHR mice-an apparent 
“feminization” of the femur (not observed in ΔIGF-1R 
mice)-indicates a significant difference in the interaction 
of GH and IGF-1 with sex steroids. Indeed, mice exhibit 
profound sex-dependent differences in the pulsatility 
and amplitude of GH secretion that results in sexually 
dimorphic expression of GH target genes (48), providing 
one possible explanation for the gender specificity of 
the phenotypes the ΔGHR mice. Alternatively, it is known 
that osteoblasts that reside at the periosteal surface 
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arise from precursors distinct from osteoblasts in the 
trabecular compartment, and evidence suggests these 
cells may have a differential response to PTH and 
estrogen (49). In addition, numerous studies, in both 
humans and animal models, have demonstrated that 
estrogen is predominantly responsible for periosteal 
expansion in males, converted from androgens by 
aromatase (50). In this regard, aromatase expression in 
bone is regulated by a promoter responsive to class I 
cytokines (51), and the GHR is class I cytokine receptor 
(52). Thus, it is an intriguing possibility, currently under 
investigation, that the failure of periosteal expansion 
observed in male ΔGHR mice might result from a 
reduction of GH-stimulated aromatase expression, and 
thus, ironically, the resultant lack of converted estrogen 
that would normally stimulate periosteal expansion 
produces a more “feminine” bone in male ΔGHR mice, 
while estrogen-replete females remain unaffected. 
In summary, our studies demonstrate that the GHR is 
required for normal postnatal bone development in 
both sexes. As may be expected, GH appears to serve a 
primary function in modulating local IGF-1 action. 
However, osteoblast-restricted disruption of the GHR in 
male mice resulted in “feminization” of bone geometry 
in adult animals, suggesting GH may function to a 
greater extent than previously appreciated in establish- 
ing the sexual dimorphism of the skeleton.   
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